Navigation Links
Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
Date:7/23/2008

VEDBAEK, Denmark, July 24 /PRNewswire-FirstCall/ -- Frost & Sullivan has announced the selection of Exiqon as the recipient of its 2008 Growth Strategy Leadership Award in the molecular diagnostic market. This award follows Frost & Sullivan's most recent analysis of the molecular diagnostic market.

Exiqon was selected for this award because of the company's acquisition of Oncotech, a market leader in the field of in vitro therapy selection testing for cancer. The research team at Frost & Sullivan viewed the acquisition of Oncotech by Exiqon as both well-timed and well-executed on the heels of the company's highly successful May 2007 IPO. .

The acquisition of Oncotech allowed the two companies to combine resources to become a leading supplier of molecular diagnostic tests based on proprietary miRNA biomarkers. "Combining the two companies has allowed Exiqon to master a number of the most significant challenges in building a platform for its future molecular diagnostic business in the US," says CEO Lars Kongsbak.

"We are dedicated to personalizing the treatment selection for cancer patients. This acquisition increases the likelihood of success and the speed in which new molecular diagnostic products can be marketed by Exiqon" continues Kongasbak; "Our goal is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment."

Through Oncotech, Exiqon markets diagnostic products that enable doctors to test whether their patients are resistant to chemotherapies prior to subscribing a treatment (the 'Extreme Drug Resistance-test'). Oncotech provides a strategic competitive advantage and a clear path to the market for Exiqon's new diagnostic products. Exiqon has already established itself as one of the market's leading providers of research products for gene expression analysis based on the LNA(TM) technology.

Frost & Sullivan does not accept nominations or submissions for Frost & Sullivan Awards. The sele
'/>"/>

SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
2. Exiqon: Major Shareholder Announcement
3. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
4. Spherix Receives NASDAQ Bid Price Deficiency Letter
5. Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
6. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
7. Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. Lorus Therapeutics Receives $600 Thousand From Escrow Account
10. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
11. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... REYKJAVIK, Iceland, November 24 /PRNewswire-F... today announced that it has received notice from,...y,s common stock will be,suspended as of November ...Securities and Exchange Commission, which will rem...unless the company files an appeal to the Nasdaq,L...
(Date:11/24/2009)...O, Calif., Nov. 24 Neuro...ompany focused on developing and commercializing n...at Anthony DiTonno, President and Chief Executive ...l Piper Jaffray Health Care Conference, to be held...n New York, New York. ,, Mr. DiTonno and Steph...
(Date:11/24/2009)...: HTL , TORONTO, Nov. 24 /PRNewswire-FirstCal...alotto Capital Inc., a leading provider of advance...research and fertility clinic markets, today repor...d quarter ended September 30, 2009. , , Q3 200...mpared with $1.43 million in Q3 2008, - Gross...
(Date:11/24/2009)... Program Connects Customers with Partners Validat...NA Genotek Products , Ott..., a leading provider of products for biological sa...day announced its new global partner program. The ...notek,s partner community and is designed to help ...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...L(R), SARATOGA SPRINGS, N.Y., Jan. 22 Palio, an,...ed to announce that Shire,Pharmaceuticals (LSE: SH...gency of record to lead the professional advertisi...rt of Shire,s renal business unit., "We are excit...k on,behalf of this important product. And, we loo...
... Inc., a fully,integrated critical care biopharmac... has been elected as an independent member of the ... Chief Financial Officer of,MedImmune, will chair ...te to have an executive with Lota,s background and...ant time in the company,s,history," said David Sha...
...icals,Inc. (NYSE: BRL ) today announced that the ...h & Urology, Division of Ortho-McNeil-Janssen,Phar...t to settle the,outstanding patent litigation invo...ceptive product, ORTHO TRI-CYCLEN(R) LO (norgestim... Court for the District of New Jersey,has postpone...
Other Biology Technology:Shire Engages Palio 2Shire Engages Palio 3Lota Zoth Elected to Ikaria Board and Named Audit Committee Chair 2Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation 2Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation 3
(Date:11/24/2009)...ries from collapsing have been true life-savers. B...eded -- once the arteries are strengthened, they b...ce but to leave them in place. , Prof. Meital Zi...medical Engineering has developed a new patent-pen...re needed, then dissolves. , "Our new composite ...
(Date:11/24/2009)...cal Toxicology (ACMT) have signed an agreement to ...Medical Toxicology (JMT), the official journal of...usly published by the University of Pennsylvania P... international, peer-reviewed journal, is dedicate... toxicology. The quarterly journal focuses on the...
(Date:11/24/2009)...ecrets of the earth,s history locked in its icy de...le information on the environments that have been ... Now, a team of researchers from nine institutions...10 million dollars by the National Science Foundat...ally. These scientists will drill through the West...
Breaking Biology News(10 mins):A coating for life 2Springer and the American College of Medical Toxicology to work together 2LSU gets to the bottom of things -- in Antarctica 2After Major Ruling on Unsafe Lead Levels in Paint Experts Reveal How You Can Ensure Your Kids Are Safe 49465 1After Major Ruling on Unsafe Lead Levels in Paint Experts Reveal How You Can Ensure Your Kids Are Safe 49465 2American Dental Hygienists Association and Johnson 26 Johnson Healthcare Products Division of McNEIL PPC Inc Announce Honorees of HYGIENIST HERO 28 49463 1American Dental Hygienists Association and Johnson 26 Johnson Healthcare Products Division of McNEIL PPC Inc Announce Honorees of HYGIENIST HERO 28 49463 2American Dental Hygienists Association and Johnson 26 Johnson Healthcare Products Division of McNEIL PPC Inc Announce Honorees of HYGIENIST HERO 28 49463 3Arizona Heart Institute Enrolls First Patient in Anaconda 28TM 29 Investigational Study for the Treatment of Abdominal Aortic Aneurysm 49462 1Arizona Heart Institute Enrolls First Patient in Anaconda 28TM 29 Investigational Study for the Treatment of Abdominal Aortic Aneurysm 49462 2Arizona Heart Institute Enrolls First Patient in Anaconda 28TM 29 Investigational Study for the Treatment of Abdominal Aortic Aneurysm 49462 3
...stem that transports gene silencing nanoparticles ... sarcoma in an animal model of the disease. , In ...lled transferrin that normally delivers iron into ... siRNA (short interfering RNA) encased in nano-siz...t a specific growth-promoting gene called EWS-FLI1...
...ention of the word "virus" stirs up memories of pa...recent years, scientists have been trying to turn ...ght against cancer. , Through genetic engineering,... of their natural abilities to infiltrate, command...s and not surrounding healthy tissue. , Several o...
...y-wide initiative to speed development of new medi...cs, the Food and Drug Administration (FDA) today i...a Submissions." , Pharmacogenomics allows health c...,s profile of drug response and predict the best p...example, genomic tests are helping to identify can...
Other Biology News:Novel gene-silencing nanoparticles shown to inhibit Ewing's sarcoma 2Novel gene-silencing nanoparticles shown to inhibit Ewing's sarcoma 3Turning viruses into allies against cancer 2Turning viruses into allies against cancer 3Turning viruses into allies against cancer 4FDA Works To Speed The Advent Of New, More Effective Personalized Medicines 2FDA Works To Speed The Advent Of New, More Effective Personalized Medicines 3
Mouse Anti-CBF-B Monoclonal Antibody, Unconjugated, Clone G-2 from Santa Cruz Biotechnology, Inc.
Rabbit Anti-Endothelin B Receptor Like Protein 2 Polyclonal Antibody, Unconjugated from GeneTex
Mouse Anti-HSV-2 gD Monoclonal Antibody, Unconjugated, Clone 0191 from Santa Cruz Biotechnology, Inc.
Rabbit Anti-QKI Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Biology Products: